Enhancement of anti-tumor immunity by high levels of Th1 and Th17 with a combination of dendritic cell fusion hybrids and regulatory T cell depletion in pancreatic cancer

Oncology Reports

Volumn 22, Issue 2, 2009, Pages 337-343

  Yamamoto, Masashi ^a   Kamigaki, Takashi ^a   Yamashita, Kimihiro ^a   Hori, Yuichi ^a   Hasegawa, Hiroshi ^a   Kuroda, Daisuke ^a   Moriyama, Hiroaki ^a   Nagata, Masao ^a   Ku, Yonson ^a   Kuroda, Yoshikazu ^a  

^a KOBE UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Dendritic cell tumor cell fusion hybrids; Interleukin 17; Pancreatic cancer; Regulatory T cell; Th1 Th2 cytokines

Indexed keywords

BASILIXIMAB; CYTOKINE; DENDRITIC CELL VACCINE; GAMMA INTERFERON;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER CELL CULTURE; CANCER IMMUNIZATION; CANCER SURVIVAL; CELL ASSAY; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; CYTOTOXICITY; DENDRITIC CELL; EFFECTOR CELL; ENZYME LINKED IMMUNOSPOT ASSAY; FEMALE; MOUSE; NATURAL KILLER CELL; NONHUMAN; PANCREAS CANCER; PRIORITY JOURNAL; PROTEIN SECRETION; PROVOCATION TEST; REGULATORY T LYMPHOCYTE; T CELL DEPLETION; TH1 CELL; TH17 CELL; TH2 CELL; TUMOR GROWTH; TUMOR IMMUNITY;

ANIMALS; CANCER VACCINES; DENDRITIC CELLS; FEMALE; INTERLEUKIN-10; INTERLEUKIN-17; INTERLEUKIN-2 RECEPTOR ALPHA SUBUNIT; INTERLEUKIN-6; KILLER CELLS, NATURAL; LYMPHOCYTE DEPLETION; MICE; MICE, INBRED C57BL; PANCREATIC NEOPLASMS; T-LYMPHOCYTES, CYTOTOXIC; T-LYMPHOCYTES, REGULATORY; TH1 CELLS; VACCINATION;

EID: 68349086644     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or_00000442     Document Type: Article

References (34)

1. Porgador A and Gilboa E: Bone marrow-generated dendritic cells pulsed with a class I-restricted peptide are potent inducers of cytotoxic T lymphocytes. J Exp Med 182: 255-260, 1995.
2. Steinman RM: The dendritic cell system and its role in immunogenicity. Annu Rev Immunol 9: 271-296, 1991.
3. Kim HS, Choo YS, Koo T, et al: Enhancement of antitumor immunity of dendritic cells pulsed with heat-treated tumor lysate in murine pancreatic cancer. Immunol Lett 103: 142-148, 2006.
4. Wolkers MC, Brouwenstijn N, Bakker AH, Toebes M and Schumacher TN: Antigen bias in T cell cross-priming. Science 304: 1314-1317, 2004.
5. Galea-Lauri J, Wells JW, Darling D, Harrison P and Farzaneh F: Strategies for antigen choice and priming of dendritic cells influence the polarization and efficacy of antitumor T-cell responses in dendritic cell-based cancer vaccination. Cancer Immunol Immunother 53: 963-977, 2004.
6. Kao JY, Zhang M, Chen CM and Chen JJ: Superior efficacy of dendritic cell-tumor fusion vaccine compared with tumor lysate-pulsed dendritic cell vaccine in colon cancer. Immunol Lett 101: 154-159, 2005.
7. McConnell EJ, Pathangey LB, Madsen CS, Gendler SJ and Mukherjee P: Dendritic cell-tumor cell fusion and staphylococcal enterotoxin B treatment in a pancreatic tumor model. J Surg Res 107: 196-202, 2002.
8. Yasuda T, Kamigaki T, Kawasaki K, et al: Superior anti-tumor protection and therapeutic efficacy of vaccination with allogeneic and semiallogeneic dendritic cell/tumor cell fusion hybrids for murine colon adenocarcinoma. Cancer Immunol Immunother 56: 1025-1036, 2007.
9. Galea-Lauri J, Darling D, Mufti G, Harrison P and Farzaneh F: Eliciting cytotoxic T lymphocytes against acute myeloid leukemia-derived antigens: evaluation of dendritic cell-leukemia cell hybrids and other antigen-loading strategies for dendritic cell-based vaccination. Cancer Immunol Immunother 51: 299-310, 2002.
10. Gong J, Avigan D, Chen D, et al: Activation of antitumor cytotoxic T lymphocytes by fusions of human dendritic cells and breast carcinoma cells. Proc Natl Acad Sci USA 97: 2715-2718, 2000.
11. Avigan D, Vasir B, Gong J, et al: Fusion cell vaccination of patients with metastatic breast and renal cancer induces immunological and clinical responses. Clin Cancer Res 10: 4699-4708, 2004.
12. Imura K, Ueda Y, Hayashi T, et al: Induction of cytotoxic T lymphocytes against human cancer cell lines using dendritic cell-tumor cell hybrids generated by a newly developed electrofusion technique. Int J Oncol 29: 531-539, 2006.
13. + regulatory T cells: their common role in controlling autoimmunity, tumor immunity, and transplantation tolerance. Immunol Rev 182: 18-32, 2001.
14. + regulatory T cells for immunologic self-tolerance and negative control of immune responses. Annu Rev Immunol 22: 531-562, 2004.
15. Fontenot JD and Rudensky AY: A well adapted regulatory contrivance: regulatory T cell development and the fork-head family transcription factor Foxp3. Nat Immunol 6: 331-337, 2005.
16. Malek TR and Bayer AL: Tolerance, not immunity, crucially depends on IL-2. Nat Rev Immunol 4: 665-674, 2004.
17. Read S, Malmstrom V and Powrie F: Cytotoxic T lymphocyte-associated antigen 4 plays an essential role in the function of CD25(+)CD4(+) regulatory cells that control intestinal inflammation. J Exp Med 192: 295-302, 2000.
18. Sakaguchi S, Yamaguchi T, Nomura T and Ono M: Regulatory T cells and immune tolerance. Cell 133: 775-787, 2008.
19. Ermann J, Szanya V, Ford GS, Paragas V, Fathman CG and Lejon K: CD4(+)CD25(+) T cells facilitate the induction of T cell anergy. J Immunol 167: 4271-4275, 2001.
20. Liyanage UK, Goedegebuure PS, Moore TT, et al: Increased prevalence of regulatory T cells (Treg) is induced by pancreas adenocarcinoma. J Immunother 29: 416-424, 2006.
21. Dannull J, Su Z, Rizzieri D, et al: Enhancement of vaccinemediated antitumor immunity in cancer patients after depletion of regulatory T cells. J Clin Invest 115: 3623-3633, 2005.
22. Lutz MB, Kukutsch N, Ogilvie AL, et al: An advanced culture method for generating large quantities of highly pure dendritic cells from mouse bone marrow. J Immunol Methods 223: 77-92, 1999.
23. Wang J, Saffold S, Cao X, Krauss J and Chen W: Eliciting T cell immunity against poorly immunogenic tumors by immunization with dendritic cell-tumor fusion vaccines. J Immunol 161: 5516-5524, 1998.
24. + regulatory T cells in the regional lymph node. J Exp Med 202: 771-781, 2005.
25. + T cells in peripheral blood from advanced pancreatic cancer patients. Pancreas 33: 386-390, 2006.
26. + regulatory T cells promotes a tumor-specific immune response in pancreas cancer-bearing mice. Ann Surg Oncol 13: 1252-1258, 2006.
27. Wald O, Weiss ID, Wald H, et al: IFN-gamma acts on T cells to induce NK cell mobilization and accumulation in target organs. J Immunol 176: 4716-4729, 2006.
28. Karimi K, Boudreau JE, Fraser K, et al: Enhanced antitumor immunity elicited by dendritic cell vaccines is a result of their ability to engage both CTL and IFN gamma-producing NK cells. Mol Ther 16: 411-418, 2008.
29. Zhang M, Berndt BE, Chen JJ and Kao JY: Expression of a soluble TGF-beta receptor by tumor cells enhances dendritic cell/tumor fusion vaccine efficacy. J Immunol 181: 3690-3697, 2008.
30. + regulatory T cells. J Immunol 174: 90-98, 2005.
31. + T cells. J Immunol 173: 5008-5020, 2004.
32. Zhou L, Lopes JE, Chong MM, et al: TGF-beta-induced Foxp3 inhibits T(H)17 cell differentiation by antagonizing ROR gammat function. Nature 453: 236-240, 2008.
33. Kryczek I, Wei S, Zou L, et al: Cutting edge: Th17 and regulatory T cell dynamics and the regulation by IL-2 in the tumor microenvironment. J Immunol 178: 6730-6733, 2007.
34. Boe A, Baiocchi M, Carbonatto M, Papoian R and Serlupi-Crescenzi O: Interleukin 6 knock-out mice are resistant to antigen-induced experimental arthritis. Cytokine 11: 1057-1064, 1999.